文献速递脊柱关节炎

阿普米司特治疗早期寡关节型银屑病关节炎:FOREMOST随机对照试验第16周主要结局

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial.
PubMed 文献 · Ann Rheum Dis · 2024-10-21

FOREMOST试验为4期多中心随机双盲安慰剂对照研究,纳入308例早期寡关节型银屑病关节炎患者,按2:1随机接受阿普米司特30 mg每日两次或安慰剂治疗24周。第16周时,阿普米司特组基于哨兵关节的MDA-Joints达标率33.9%,安慰剂组16.0%(p=0.0008);基于全部关节的达标率分别为21.3%和7.9%(名义p=0.0028)。

要点

  • 阿普米司特组第16周哨兵关节MDA-Joints达标率33.9%,安慰剂组16.0%(p=0.0008)。
  • 全部关节MDA-Joints达标率阿普米司特组21.3%,安慰剂组7.9%(名义p=0.0028)。
  • 患者报告结局、临床疾病活动度和皮肤受累在阿普米司特组较安慰剂组改善更明显。

核心结论

  • FOREMOST是首个专为早期寡关节型银屑病关节炎设计的随机对照试验,显示阿普米司特改善临床和患者报告结局。
  • 作者认为该试验可能为这类银屑病关节炎患者的最佳管理提供参考。

研究设计与样本

  • FOREMOST(NCT03747939)为4期多中心、随机、双盲、安慰剂对照试验。
  • 患者为早期寡关节型银屑病关节炎(症状持续时间≤5年;肿胀关节>1但≤4个且压痛关节>1但≤4个;活动关节总数2-8个)。
  • 患者按2:1随机接受阿普米司特30 mg每日两次或安慰剂治疗24周,第16周允许早期逃逸。
  • 共随机308例患者(阿普米司特组n=203;安慰剂组n=105),平均(SD)银屑病关节炎病程9.9(10.2)个月,平均(SD)年龄50.9(12.5)岁,39.9%的患者正在使用传统合成改善病情抗风湿药。

主要发现

  • 第16周时,阿普米司特组基于哨兵关节的MDA-Joints达标率为33.9%,安慰剂组为16.0%(p=0.0008)。
  • 第16周时,阿普米司特组基于全部关节的MDA-Joints达标率为21.3%,安慰剂组为7.9%(名义p=0.0028)。
  • 患者报告结局、临床疾病活动度和皮肤受累在阿普米司特组较安慰剂组改善更明显。

关键数值与推荐

  • 主要终点为第16周达到基于哨兵关节(基线受累关节)的MDA-Joints(改良MDA,要求肿胀关节≤1个且压痛关节≤1个)的患者比例,采用无应答者填补与多重填补相结合。
  • 探索性分析评估全部关节的MDA-Joints达标率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. METHODS: FOREMOST (NCT03747939) was a phase 4 multicentre, randomised, double-blind, placebo-controlled trial. Patients had early (symptom duration ≤5 years) oligoarticular PsA (>1 but ≤4 swollen and >1 but ≤4 tender joints; 2-8 total active joints). Patients were randomised 2:1 to apremilast 30 mg two times per day or placebo for 24 weeks, with an early escape at week 16. The primary endpoint was the proportion of patients at week 16 who achieved minimal disease activity (MDA)-Joints (modification of MDA mandating ≤1 swollen joint and ≤1 tender joint) based on sentinel joints (those affected at baseline) with a combination of non-responder imputation and multiple imputations. Exploratory analysis assessed all joints. RESULTS: Of 308 patients randomised (apremilast: n=203; placebo: n=105), mean (SD) PsA duration was 9.9 (10.2) months, mean (SD) age was 50.9 (12.5) years and 39.9% of patients were using a conventional synthetic disease-modifying antirheumatic drug. MDA-Joints (sentinel joints (primary endpoint) and all joints) were achieved by significantly more patients with apremilast (33.9% and 21.3%) vs placebo (16.0% and 7.9%) at week 16 (p=0.0008 and nominal p=0.0028, respectively). Greater improvements in patient-reported outcomes, clinical disease activity and skin involvement were also seen with apremilast versus placebo. CONCLUSIONS: FOREMOST is the first randomised controlled trial designed for early oligoarticular PsA and showed apremilast improves clinical and patient-reported outcomes. This trial may inform the optimal management of PsA in these patients. TRIAL REGISTRATION NUMBER: NCT03747939.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gossec L, Coates LC, Gladman DD, et al. Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial. Ann Rheum Dis. 2024. PMID: 39164067. doi:10.1136/ard-2024-225833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。